文章：

多发性骨髓瘤移植后维持治疗：不断变化的格局

Posttransplant maintenance therapy in multiple myeloma: the changing landscape

原文发布日期：2017-03-24

DOI: 10.1038/bcj.2017.23

类型: Review

开放获取: 是

英文摘要：

Transplant-eligible patients with multiple myeloma (MM) now have extended survival after diagnosis owing to effective modern treatment strategies that include new agents in induction therapy, autologous stem cell transplant (ASCT), consolidation therapy and posttransplant maintenance therapy. Standard of care for newly diagnosed, fit patients includes ASCT and, often nowadays, posttransplant maintenance. Several large studies have shown the efficacy of maintenance with thalidomide, lenalidomide and bortezomib in the treatment scheme of MM with regards to prolonging progression-free survival and, to a lesser degree, overall survival. Herein we discuss the data currently available to support the use of maintenance therapy in patients after ASCT as well as the newer available agents that may be a part of its changing landscape in the years to come.

摘要翻译： 

适合移植的多发性骨髓瘤（MM）患者如今在诊断后能获得更长的生存期，这得益于有效的现代治疗策略，包括诱导治疗中的新药、自体干细胞移植（ASCT）、巩固治疗以及移植后维持治疗。对于新诊断的适宜患者，标准治疗包括ASCT，并且在当前实践中常包含移植后维持治疗。多项大型研究已证实，沙利度胺、来那度胺和硼替佐米在MM治疗方案中作为维持治疗，能有效延长无进展生存期，并在较小程度上改善总生存期。本文我们将讨论目前支持在ASCT后患者中使用维持治疗的现有数据，以及未来可能改变治疗格局的新可用药物。

原文链接：

Posttransplant maintenance therapy in multiple myeloma: the changing landscape